- Home
- NUTR vs CNTX Comparison
NUTR vs CNTX Comparison
Compare NUTR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- CNTX
- Stock Information
- Founded
- NUTR 2013
- CNTX 2015
- Country
- NUTR Indonesia
- CNTX United States
- Employees
- NUTR N/A
- CNTX N/A
- Industry
- NUTR
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NUTR
- CNTX Health Care
- Exchange
- NUTR Nasdaq
- CNTX Nasdaq
- Market Cap
- NUTR 94.1M
- CNTX 75.6M
- IPO Year
- NUTR 2025
- CNTX 2021
- Fundamental
- Price
- NUTR $9.30
- CNTX $1.10
- Analyst Decision
- NUTR
- CNTX Strong Buy
- Analyst Count
- NUTR 0
- CNTX 7
- Target Price
- NUTR N/A
- CNTX $5.20
- AVG Volume (30 Days)
- NUTR 2.7M
- CNTX 204.2K
- Earning Date
- NUTR 11-02-2025
- CNTX 11-05-2025
- Dividend Yield
- NUTR N/A
- CNTX N/A
- EPS Growth
- NUTR N/A
- CNTX N/A
- EPS
- NUTR 0.00
- CNTX N/A
- Revenue
- NUTR $1,743,679.00
- CNTX N/A
- Revenue This Year
- NUTR N/A
- CNTX N/A
- Revenue Next Year
- NUTR N/A
- CNTX N/A
- P/E Ratio
- NUTR $3,995.74
- CNTX N/A
- Revenue Growth
- NUTR N/A
- CNTX N/A
- 52 Week Low
- NUTR $3.40
- CNTX $0.49
- 52 Week High
- NUTR $9.50
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- CNTX 73.54
- Support Level
- NUTR N/A
- CNTX $0.85
- Resistance Level
- NUTR N/A
- CNTX $0.99
- Average True Range (ATR)
- NUTR 0.00
- CNTX 0.07
- MACD
- NUTR 0.00
- CNTX 0.01
- Stochastic Oscillator
- NUTR 0.00
- CNTX 82.25
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.